Feng Zhang

Bio: Feng Zhang is an academic researcher from Fudan University. The author has contributed to research in topics: Medicine & Materials science. The author has an hindex of 172, co-authored 1278 publications receiving 181865 citations. Previous affiliations of Feng Zhang include Cincinnati Children's Hospital Medical Center & Nanjing Medical University.

Synthesis of titanium dioxide films by ion beam enhanced deposition

Abstract: Titanium dioxide films were prepared by ion beam enhanced deposition (IBED), where the films were synthesized by depositing titanium atoms and simultaneously bombarding with Ne+, Ar+ and Xe+ ion beams respectively at an energy of 40 keV in an O2 environment. Rutherford backscattering spectroscopy (RBS), X-ray photoelectron spectroscopy (XPS), and X-ray diffraction (XRD) and Raman spectroscopy were used to characterize the deposited films. It was found that the O Ti ratio of films deposited is less than 2 : 1. XPS analysis shows that Ti2+, Ti3+ and Ti4+ chemical states exist on the titanium oxide films. The films deposited at different ion beam bombardment are principally crystalline TiO2 with a rutile structure. The films deposited with Ne+ bombardment exhibit a (1 0 0) preferred orientation. Films deposited with Xe+ bombardment exhibit a high (1 0 0) orientation and increase the (1 0 0) orientation with decreasing ion beam current density. The lattice parameter of the deposited films is larger than that of bulk materials. The grain size of the films is between 20 and 60 nm and decreases with increasing mass of bombarding ions.

Effects of rapid recurrent annealing on structure and magneto‐optical properties of garnet films

Abstract: A new method to improve the morphology and the microstructure of sputtered bismuth‐substituted garnet films for optical storage is discussed. The method employs a high ramp up rate and recurrent annealing as well as quenching in an air environment, which results in smaller grain size, smoother surface, and less void volume in the garnet films than that from a conventional oven annealing. We have discovered that samples prepared with a more recurrent annealing only appeared as a single garnet phase, and the samples with a less recurrent annealing appeared as a garnet phase as well as DyFeO3 phase. We observed the microstructure of the annealed films with scanning electron microscopy (SEM). By applying the new method, the as‐deposited films had been successfully crystallized to the (BiDy)3(FeGa)5O12 garnet phase with the grain size of about 300–400 A. They exhibited excellent magneto‐optical properties with a high coercive force about 1300 Oe and an effective Kerr angle of 1.5°. The crystallization process ...

Heat resistance single-component silane modified polyurethane sealant and preparation method thereof

Abstract: The invention relates to a heat resistance single-component silane modified polyurethane sealant and a preparation method thereof, which belong to the technical field of sealant. Use temperature of the existing silane modified polyurethane sealant all ranges from 0 to 100 DEG C, the existing silane modified polyurethane sealant can bear 120 DEG C for a short time, and a problem of remarkable mechanical property weakening exists if the existing silane modified polyurethane sealant is under a high temperature condition for a long time. The heat resistance single-component silane modified polyurethane sealant is mainly characterized by comprising (A) 30-40% Wt of silane modified polyurethane base polymer, (B) 30-45% Wt of filler, (C) 8-15% Wt of plasticizer, (D) 1-5% Wt of colorant, (E) 0.5-1% Wt of ultraviolet absorber, (F) 0.5-1% Wt of light stabilizer, (G) 0.4-1.5% Wt of heat resisting synergist, (H) 0.5-2% Wt of additive TI, (I) 0.5-2% Wt of silane coupling agent, (K) 0.5-2% Wt of thixtropic agent and (L) 0.2-1% Wt of catalyst. The heat resistance single-component silane modified polyurethane sealant has the advantages that heat resistance performance is greatly improved, and mechanical property after high-temperature ageing is kept well. The heat resistance single-component silane modified polyurethane sealant is mainly used in the industrial fields of automobile industry, railway transportation industry, and new energy industry and the like.

Enhancing CTR Prediction with Context-Aware Feature Representation Learning

Abstract: CTR prediction has been widely used in the real world. Many methods model feature interaction to improve their performance. However, most methods only learn a fixed representation for each feature without considering the varying importance of each feature under different contexts, resulting in inferior performance. Recently, several methods tried to learn vector-level weights for feature representations to address the fixed representation issue. However, they only produce linear transformations to refine the fixed feature representations, which are still not flexible enough to capture the varying importance of each feature under different contexts. In this paper, we propose a novel module named Feature Refinement Network (FRNet), which learns context-aware feature representations at bit-level for each feature in different contexts. FRNet consists of two key components: 1) Information Extraction Unit (IEU), which captures contextual information and cross-feature relationships to guide context-aware feature refinement; and 2) Complementary Selection Gate (CSGate), which adaptively integrates the original and complementary feature representations learned in IEU with bit-level weights. Notably, FRNet is orthogonal to existing CTR methods and thus can be applied in many existing methods to boost their performance. Comprehensive experiments are conducted to verify the effectiveness, efficiency, and compatibility of FRNet.

疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A

Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1（PfPMP1）与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用，在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员，通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Abstract: ABCD : Appropriate Blood pressure Control in Diabetes ABI : ankle–brachial index ABPM : ambulatory blood pressure monitoring ACCESS : Acute Candesartan Cilexetil Therapy in Stroke Survival ACCOMPLISH : Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE : angiotensin-converting enzyme ACTIVE I : Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ADVANCE : Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation AHEAD : Action for HEAlth in Diabetes ALLHAT : Antihypertensive and Lipid-Lowering Treatment to Prevent Heart ATtack ALTITUDE : ALiskiren Trial In Type 2 Diabetes Using Cardio-renal Endpoints ANTIPAF : ANgioTensin II Antagonist In Paroxysmal Atrial Fibrillation APOLLO : A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People ARB : angiotensin receptor blocker ARIC : Atherosclerosis Risk In Communities ARR : aldosterone renin ratio ASCOT : Anglo-Scandinavian Cardiac Outcomes Trial ASCOT-LLA : Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm ASTRAL : Angioplasty and STenting for Renal Artery Lesions A-V : atrioventricular BB : beta-blocker BMI : body mass index BP : blood pressure BSA : body surface area CA : calcium antagonist CABG : coronary artery bypass graft CAPPP : CAPtopril Prevention Project CAPRAF : CAndesartan in the Prevention of Relapsing Atrial Fibrillation CHD : coronary heart disease CHHIPS : Controlling Hypertension and Hypertension Immediately Post-Stroke CKD : chronic kidney disease CKD-EPI : Chronic Kidney Disease—EPIdemiology collaboration CONVINCE : Controlled ONset Verapamil INvestigation of CV Endpoints CT : computed tomography CV : cardiovascular CVD : cardiovascular disease D : diuretic DASH : Dietary Approaches to Stop Hypertension DBP : diastolic blood pressure DCCT : Diabetes Control and Complications Study DIRECT : DIabetic REtinopathy Candesartan Trials DM : diabetes mellitus DPP-4 : dipeptidyl peptidase 4 EAS : European Atherosclerosis Society EASD : European Association for the Study of Diabetes ECG : electrocardiogram EF : ejection fraction eGFR : estimated glomerular filtration rate ELSA : European Lacidipine Study on Atherosclerosis ESC : European Society of Cardiology ESH : European Society of Hypertension ESRD : end-stage renal disease EXPLOR : Amlodipine–Valsartan Combination Decreases Central Systolic Blood Pressure more Effectively than the Amlodipine–Atenolol Combination FDA : U.S. Food and Drug Administration FEVER : Felodipine EVent Reduction study GISSI-AF : Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation HbA1c : glycated haemoglobin HBPM : home blood pressure monitoring HOPE : Heart Outcomes Prevention Evaluation HOT : Hypertension Optimal Treatment HRT : hormone replacement therapy HT : hypertension HYVET : HYpertension in the Very Elderly Trial IMT : intima-media thickness I-PRESERVE : Irbesartan in Heart Failure with Preserved Systolic Function INTERHEART : Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction in 52 Countries INVEST : INternational VErapamil SR/T Trandolapril ISH : Isolated systolic hypertension JNC : Joint National Committee JUPITER : Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin LAVi : left atrial volume index LIFE : Losartan Intervention For Endpoint Reduction in Hypertensives LV : left ventricle/left ventricular LVH : left ventricular hypertrophy LVM : left ventricular mass MDRD : Modification of Diet in Renal Disease MRFIT : Multiple Risk Factor Intervention Trial MRI : magnetic resonance imaging NORDIL : The Nordic Diltiazem Intervention study OC : oral contraceptive OD : organ damage ONTARGET : ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial PAD : peripheral artery disease PATHS : Prevention And Treatment of Hypertension Study PCI : percutaneous coronary intervention PPAR : peroxisome proliferator-activated receptor PREVEND : Prevention of REnal and Vascular ENdstage Disease PROFESS : Prevention Regimen for Effectively Avoiding Secondary Strokes PROGRESS : Perindopril Protection Against Recurrent Stroke Study PWV : pulse wave velocity QALY : Quality adjusted life years RAA : renin-angiotensin-aldosterone RAS : renin-angiotensin system RCT : randomized controlled trials RF : risk factor ROADMAP : Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention SBP : systolic blood pressure SCAST : Angiotensin-Receptor Blocker Candesartan for Treatment of Acute STroke SCOPE : Study on COgnition and Prognosis in the Elderly SCORE : Systematic COronary Risk Evaluation SHEP : Systolic Hypertension in the Elderly Program STOP : Swedish Trials in Old Patients with Hypertension STOP-2 : The second Swedish Trial in Old Patients with Hypertension SYSTCHINA : SYSTolic Hypertension in the Elderly: Chinese trial SYSTEUR : SYSTolic Hypertension in Europe TIA : transient ischaemic attack TOHP : Trials Of Hypertension Prevention TRANSCEND : Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease UKPDS : United Kingdom Prospective Diabetes Study VADT : Veterans' Affairs Diabetes Trial VALUE : Valsartan Antihypertensive Long-term Use Evaluation WHO : World Health Organization ### 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology …

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Abstract: Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems provide bacteria and archaea with adaptive immunity against viruses and plasmids by using CRISPR RNAs (crRNAs) to guide the silencing of invading nucleic acids. We show here that in a subset of these systems, the mature crRNA that is base-paired to trans-activating crRNA (tracrRNA) forms a two-RNA structure that directs the CRISPR-associated protein Cas9 to introduce double-stranded (ds) breaks in target DNA. At sites complementary to the crRNA-guide sequence, the Cas9 HNH nuclease domain cleaves the complementary strand, whereas the Cas9 RuvC-like domain cleaves the noncomplementary strand. The dual-tracrRNA:crRNA, when engineered as a single RNA chimera, also directs sequence-specific Cas9 dsDNA cleavage. Our study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.